Infectious Complications After Cystectomy: A Prospective Observational Study
Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Nov 29, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the risk of infections in patients who are scheduled to have their bladder removed, a procedure known as cystectomy. It aims to gather information about how often infections occur before and after the surgery, and to understand both the medical outcomes and the experiences of patients during their hospital stay. To do this, researchers will collect detailed medical information and track any complications that arise in the hospital and during follow-up visits at 3, 6, and 12 months after the surgery.
To be eligible for this study, participants must have a medical condition that requires bladder removal. The study is open to all adults, and the only requirement for exclusion is that a patient does not wish to take part in the trial. Participants can expect to provide their medical history, answer questions about their hospital experience, and help researchers improve care for future patients facing similar surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Disease which requires removal of the urinary bladder
- Exclusion Criteria:
- • Patient does not want to participate
About Ludwig Maximilians University Of Munich
Ludwig-Maximilians-University of Munich (LMU Munich) is a prestigious research institution in Germany, renowned for its commitment to advancing medical science and improving patient care through innovative clinical research. As a leading sponsor of clinical trials, LMU Munich leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous studies aimed at evaluating new therapeutic interventions and advancing healthcare knowledge. The university fosters collaboration among researchers, clinicians, and healthcare professionals, ensuring that trials are designed and executed with the highest ethical standards and scientific integrity. Through its dedication to excellence in research, LMU Munich aims to contribute significantly to the development of effective treatments and enhance the overall health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Outside U.S./Canada, Germany
Munich, , Germany
Patients applied
Trial Officials
Gerald Schulz, PD Dr.
Principal Investigator
Ludwig-Maximilians - University of Munich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials